Researchers at Children's Hospital of Philadelphia (CHOP) highlighted the success of anaplastic lymphoma kinase (ALK) inhibition therapy in treating hereditary neuroblastoma, a rare subset of a common ...

Researchers visualized ALK fusion proteins in real time. They showed that ALK inhibitors reshape flexible protein regions to ...

New targeted drugs transform HER2, ROS1 and ALK lung cancer care, boosting brain response and survival—while precision choices still matter.

Investigators at Massachusetts General Hospital in Boston conducted an analysis of the fusion oncogene EML4-ALK and the more well-studied epidermal growth factor receptor (EGFR) mutation among a group ...

The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...

Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-655 of 150 mg once daily Phase 2 Designed with Registrational Intent for TKI Pre-Treated Patients with ALK-Positive ...

The global market for kinase inhibitors targeting ALK-mutated NSCLC is expected to reach $5.7 billion by 2031. Credit: ridersuperone via Shutterstock. At the 2025 European Society of Medical Oncology ...

Durable activity of NVL-655 and zidesamtinib in heavily pre-treated patient populations supports ongoing Phase 2 investigation in earlier lines of treatment "Our development strategy has been anchored ...

Most patients with non-small cell lung cancer (NSCLC) that has metastasized to the brain have a dire prognosis. But Yale researchers have identified a subset of those patients with a rare genetic ...

In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month landmarks, respectively In the ...